Clinical Trial Detail

NCT ID NCT02101853
Title Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

acute lymphoblastic leukemia

Therapies

Blinatumomab

Leucovorin + Pegaspargase + Vincristine Sulfate

Mercaptopurine + Thioguanine

Asparaginase + Cyclophosphamide + Etoposide

Cytarabine + Dexamethasone + Methotrexate

Age Groups: adult child

No variant requirements are available.